The DOI matches its Crossref record; 63 of the 63 references it cites were found in a registry or an index.
Liquid versus tissue biopsy for detecting acquired resistance and tumor heterogeneity in gastrointestinal cancers
Open accessAbstract
During cancer therapy, tumor heterogeneity can drive the evolution of multiple tumor subclones harboring unique resistance mechanisms in an individual patient 1-3. Previous case reports and small case series have suggested that liquid biopsy (specifically, cell-free DNA (cfDNA)) may better capture the heterogeneity of acquired resistance 4-8. However, the effectiveness of cfDNA versus standard single-lesion tumor biopsies has not been directly compared in larger-scale prospective cohorts of patients following progression on targeted therapy. Here, in a prospective cohort of 42 patients with molecularly defined gastrointestinal cancers and acquired resistance to targeted therapy, direct comparison of postprogression cfDNA versus tumor biopsy revealed that cfDNA more frequently identified clinically relevant resistance alterations and multiple resistance mechanisms, detecting resistance alterations not found in the matched tumor biopsy in 78% of cases. Whole-exome sequencing of serial cfDNA, tumor biopsies and rapid autopsy specimens elucidated substantial geographic and evolutionary differences across lesions. Our data suggest that acquired resistance is frequently characterized by profound tumor heterogeneity, and that the emergence of multiple resistance alterations in an individual patient may represent the 'rule' rather than the 'exception'. These findings have profound therapeutic implications and highlight the potential advantages of cfDNA over tissue biopsy in the setting of acquired resistance.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“In earlier-stage disease, ctDNA-based minimal residual disease assessment may enable risk stratification after surgery or definitive therapy [47,79].”
From Precision Targeting of KRAS-Mutant Cancers: Beyond G12C Toward G12D and Pan-RAS Therapeutic Strategies (2026) · cites this paper as [79]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing
Gerlinger, M., Rowan, A. J., Horswell, S., Larkin, J., Endesfelder, D., Gronroos, E., Martinez, P., Matthews, N., Stewart, A., Tarpey, P., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1113205 · Cited by 7,774
Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies
Bettegowda, C., Sausen, M., Leary, R. J., Kinde, I., Wang, Y., Agrawal, N., Bartlett, B. R., Wang, H., Luber, B., Alani, R. M., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3007094 · Cited by 5,067
Self-citationSensitive detection of somatic point mutations in impure and heterogeneous cancer samples
Cibulskis, K., Lawrence, M. S., Carter, S. L., Sivachenko, A., Jaffe, D., Sougnez, C., Gabriel, S., Meyerson, M., Lander, E. S., & Getz, G. (2013) · Nature Biotechnology · doi:10.1038/nbt.2514 · Cited by 4,981
Self-citationTracking the Evolution of Non–Small-Cell Lung Cancer
Jamal-Hanjani, M., Wilson, G. A., McGranahan, N., Birkbak, N. J., Watkins, T. B. K., Veeriah, S., Shafi, S., Johnson, D. H., Mitter, R., Rosenthal, R., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1616288 · Cited by 2,349
Absolute quantification of somatic DNA alterations in human cancer
Carter, S. L., Cibulskis, K., Helman, E., McKenna, A., Shen, H., Zack, T., Laird, P. W., Onofrio, R. C., Winckler, W., Weir, B. A., et al. (2012) · Nature Biotechnology · doi:10.1038/nbt.2203 · Cited by 2,053
Self-citationEmergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer
Misale, S., Yaeger, R., Hobor, S., Scala, E., Janakiraman, M., Liska, D., Valtorta, E., Schiavo, R., Buscarino, M., Siravegna, G., et al. (2012) · Nature · doi:10.1038/nature11156 · Cited by 1,889
Self-citationThe molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers
Diaz Jr, L. A., Williams, R. T., Wu, J., Kinde, I., Hecht, J. R., Berlin, J., Allen, B., Bozic, I., Reiter, J. G., Nowak, M. A., et al. (2012) · Nature · doi:10.1038/nature11219 · Cited by 1,713
Strelka2: fast and accurate calling of germline and somatic variants
Kim, S., Scheffler, K., Halpern, A. L., Bekritsky, M. A., Noh, E., Källberg, M., Chen, X., Kim, Y., Beyter, D., Krusche, P., et al. (2018) · Nature Methods · doi:10.1038/s41592-018-0051-x · Cited by 1,632
Gerlinger, M., Horswell, S., Larkin, J., Rowan, A. J., Salm, M. P., Varela, I., Fisher, R., McGranahan, N., Matthews, N., Santos, C. R., et al. (2014) · Nature Genetics · doi:10.1038/ng.2891 · Cited by 1,208
Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients
Siravegna, G., Mussolin, B., Buscarino, M., Corti, G., Cassingena, A., Crisafulli, G., Ponzetti, A., Cremolini, C., Amatu, A., Lauricella, C., et al. (2015) · Nature Medicine · doi:10.1038/nm.3870 · Cited by 1,082
Self-citation
Cited by
Liquid biopsy enters the clinic — implementation issues and future challenges
Ignatiadis, M., Sledge, G. W., & Jeffrey, S. S. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-00457-x · Cited by 1,191
Ganesh, K., & Massagué, J. (2021) · Nature Medicine · doi:10.1038/s41591-020-01195-4 · Cited by 1,051
Exosome-based liquid biopsies in cancer: opportunities and challenges
Yu, W., Hurley, J., Roberts, D., Chakrabortty, S. K., Enderle, D., Noerholm, M., Breakefield, X. O., & Skog, J. K. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.01.074 · Cited by 870
High-intensity sequencing reveals the sources of plasma circulating cell-free DNA variants
Razavi, P., Li, B. T., Brown, D. N., Jung, B., Hubbell, E., Shen, R., Abida, W., Juluru, K., De Bruijn, I., Hou, C., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0652-7 · Cited by 769
Targeted therapy for hepatocellular carcinoma
Huang, A., Yang, X.-R., Chung, W.-Y., Dennison, A. R., & Zhou, J. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00264-x · Cited by 739
Metadata
- Authors
- Parikh, A. R., Leshchiner, I., Elagina, L., Goyal, L., Levovitz, C., Siravegna, G., Livitz, D., Rhrissorrakrai, K., Martin, E. E., Van Seventer, E. E., Hanna, M., Slowik, K., Utro, F., Pinto, C. J., Wong, A., Danysh, B. P., de la Cruz, F. F., Fetter, I. J., Nadres, B., Shahzade, H. A., Allen, J. N., Blaszkowsky, L. S., Clark, J. W., Giantonio, B., Murphy, J. E., Nipp, R. D., Roeland, E., Ryan, D. P., Weekes, C. D., Kwak, E. L., Faris, J. E., Wo, J. Y., Aguet, F., Dey-Guha, I., Hazar-Rethinam, M., Dias-Santagata, D., Ting, D. T., Zhu, A. X., Hong, T. S., Golub, T. R., Iafrate, A. J., Adalsteinsson, V. A., Bardelli, A., Parida, L., Juric, D., Getz, G., & Corcoran, R. B.
- Affiliations
- Harvard University (US)
- Broad Institute (US)
- IBM (United States) (US)
- Candiolo Cancer Institute (IT)
- Corresponding author
- Getz, Gad
- Corcoran, Ryan B.
- ORCID
- Parikh, Aparna R.
- Leshchiner, Ignaty
- Goyal, Lipika
- Levovitz, Chaya
- Siravegna, Giulia
- Livitz, Dimitri
- Rhrissorrakrai, Kahn
- Martin, Elizabeth E.
- Utro, Filippo
- Wong, Alicia
- Danysh, Brian P.
- de la Cruz, Ferran Fece
- Fetter, Isobel J.
- Nadres, Brandon
- Allen, Jill N.
- Blaszkowsky, Lawrence S.
- Clark, Jeffrey W.
- Giantonio, Bruce
- Nipp, Ryan D.
- Roeland, Eric
- Ryan, David P.
- Weekes, Colin D.
- Wo, Jennifer Y.
- Aguet, François
- Hazar-Rethinam, Mehlika
- Dias-Santagata, Dora
- Ting, David T.
- Zhu, Andrew X.
- Hong, Theodore S.
- Golub, Todd R.
- Iafrate, A. John
- Adalsteinsson, Viktor A.
- Bardelli, Alberto
- Parida, Laxmi
- Juric, Dejan
- Getz, Gad
- Corcoran, Ryan B.
- Venue
- Nature Medicine
- Published
- 2019-09
- Volume
- 25
- Issue
- 9
- Pages
- 1415-1421
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- PMC
- PMC6741444
- OpenAlex
- W2972422665
- Cited by
- 518
- References
- 63
- Citations by year
- 2026: 35 · 2025: 60 · 2024: 63 · 2023: 80 · 2022: 94 · 2021: 96 · 2020: 77 · 2019: 10
- FWCI
- 22.09
- Type
- journal article
- Language
- en
- Update notices
- correction (2019-11-19)
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion)
- Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion)
- Funders
- Bristol-Myers Squibb
- Eli Lilly and Company
- AstraZeneca
- GlaxoSmithKline
- Sanofi
- Celgene
- Agios Pharmaceuticals
- MacroGenics
- Ministero della Salute
- Eisai
- Associazione Italiana per la Ricerca sul Cancro
- Plexxikon
- National Institutes of Health
- Genentech
- EMD Serono
- Pharmacyclics
- Foundation Medicine
- National Cancer Institute (P50CA127003, R01CA208437, U54CA224068, K08CA166510, K12CA087723)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Keywords
- liquid biopsy, cell-free DNA, tumor heterogeneity, acquired drug resistance, gastrointestinal cancer, targeted therapy resistance, tumor subclones, circulating tumor DNA, tissue biopsy comparison, resistance mechanisms
- MeSH terms
- Exome Sequencing, Cell-Free Nucleic Acids, Liquid Biopsy, Autopsy, DNA, Neoplasm, Female, Gastrointestinal Neoplasms, Humans, Male, Middle Aged, Mutation, Cohort Studies, Genetic Heterogeneity, Drug Resistance, Neoplasm, Proto-Oncogene Proteins B-raf
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Liquid versus tissue biopsy for detecting acquired resistance and tumor heterogeneity in gastrointestinal cancers. https://app.cochat.ai/papers/10.1038/s41591-019-0561-9
- The paper
- Parikh, A. R., Leshchiner, I., Elagina, L., Goyal, L., Levovitz, C., Siravegna, G., Livitz, D., Rhrissorrakrai, K., Martin, E. E., Van Seventer, E. E., Hanna, M., Slowik, K., Utro, F., Pinto, C. J., Wong, A., Danysh, B. P., de la Cruz, F. F., Fetter, I. J., Nadres, B., . . . Corcoran, R. B. (2019). Liquid versus tissue biopsy for detecting acquired resistance and tumor heterogeneity in gastrointestinal cancers. Nature Medicine. https://doi.org/10.1038/s41591-019-0561-9
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.